辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PFE 辉瑞

交易中 05-14 11:40:07 EDT

25.78

-0.18

-0.69%

最高26.10	最低25.75	成交量843.08万
今开26.02	昨收25.96	日振幅1.35%
总市值1,466亿	流通市值1,463亿	总股本56.86亿
成交额2.18亿	换手率0.15%	流通股本56.76亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PFE","market":"US","secType":"STK","nameCN":"辉瑞","latestPrice":25.7799,"timestamp":1778773207304,"preClose":25.96,"halted":0,"volume":8430826,"delay":0,"changeRate":-0.006937596302003061,"floatShares":5675908374,"shares":5685707552,"eps":1.312648,"marketStatus":"交易中","change":-0.1801,"latestTime":"05-14 11:40:07 EDT","open":26.02,"high":26.1,"low":25.75,"amount":218402756.406412,"amplitude":0.013482,"askPrice":25.78,"askSize":1222,"bidPrice":25.77,"bidSize":2956,"shortable":3,"etf":0,"ttmEps":1.312648,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1778788800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":-819144000000,"exchange":"NYSE","adjPreClose":25.96,"dividendRate":0.066734,"preHourTrading":{"tag":"盘前","latestPrice":26.06,"preClose":25.96,"latestTime":"09:29 EDT","volume":74617,"amount":1938415.3494000002,"timestamp":1778765399940,"change":0.1,"changeRate":0.003852,"amplitude":0.006163},"postHourTrading":{"tag":"盘后","latestPrice":25.8911,"preClose":25.96,"latestTime":"19:59 EDT","volume":8974432,"amount":232974186.642999,"timestamp":1778716798446,"change":-0.0689,"changeRate":-0.002654,"amplitude":0.002696},"volumeRatio":0.63689,"impliedVol":0.1931,"impliedVolPercentile":0.0159},"requestUrl":"/m/hq/s/PFE","defaultTab":"news","newsList":[{"id":"2635842857","title":"减重赛道激战正酣：跨国巨头齐亮剑，竞争升维至全病程管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2635842857","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635842857?lang=zh_cn&edition=full","pubTime":"2026-05-13 19:54","pubTimestamp":1778673240,"startTime":"0","endTime":"0","summary":"在2026年世界防治肥胖日到来、“体重管理年”行动收官的关键节点，全球减重药物市场的火药味达到了新的浓度。从伊斯坦布尔第33届欧洲肥胖大会（ECO），到国内学术峰会，诺和诺德、礼来以及辉瑞/先为达等跨国药企与本土创新力量，不约而同地选择在这一时间窗口密集“亮剑”，发布了各自在减重领域的最新重磅数据。这并非巧合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605133736129640.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605133736129640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0306807586.USD","LU0058720904.USD","IE00BLSP4452.SGD","IE00BKVL7J92.USD","NVOX","SG9999003800.SGD","LU0234572021.USD","SG9999002232.USD","BK4532","IE00B19Z3581.USD","SG9999001176.SGD","BK4144","BK4533","BK4534","BK4592","LU1023059063.AUD","ECO","NVOH","IE00BBT3K403.USD","LU1066053197.SGD","SG9999001176.USD","LU1894683348.USD","LU0321505439.SGD","NVO","LU0225284248.USD","IE00BLSP4239.USD","LU0154236417.USD","IE0002270589.USD","IE00B19Z3B42.SGD","PFE","IE000M9KFDE8.USD","BK4581","LU1883839398.USD","LU0985481810.HKD","LU0289739699.SGD","LU1894683264.USD","BK4588","SG9999011175.SGD","LU0868494617.USD","LU0997586861.USD","LU1093756325.SGD","BK4568","LU0225771236.USD","IE00BZ1G4Q59.USD","LU0456855351.SGD","SGXZ57979304.SGD","BK4550","BK4007","BK4585","LU1057294990.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109253522","title":"辉瑞Hympavzi在欧盟27国及冰岛、列支敦士登和挪威获得全面营销授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1109253522","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109253522?lang=zh_cn&edition=full","pubTime":"2026-05-13 18:47","pubTimestamp":1778669256,"startTime":"0","endTime":"0","summary":"辉瑞公司宣布，其药物Hympavzi的营销授权现已全面覆盖欧盟全部27个成员国，并扩展至冰岛、列支敦士登和挪威。这一授权为相关市场提供了统一的准入许可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","IE00B19Z3B42.SGD","SG9999002232.USD","LU0868494617.USD","LU0456855351.SGD","SG9999011175.SGD","LU0225284248.USD","LU1894683264.USD","IE00B3T34201.USD","LU0170899867.USD","LU1066053197.SGD","LU0306807586.USD","LU1057294990.SGD","LU0122379950.USD","LU0321505868.SGD","LU1066051498.USD","SG9999002224.SGD","BK4533","BK4585","SG9999013999.USD","IE00BLSP4452.SGD","SGXZ57979304.SGD","LU0234572021.USD","LU1023059063.AUD","BK4599","LU0225771236.USD","LU0289739699.SGD","LU0058720904.USD","LU1883839398.USD","IE00BLSP4239.USD","IE00B19Z3581.USD","SG9999003800.SGD","BK4568","LU1894683348.USD","LU0985481810.HKD","BK4550","LU0321505439.SGD","BK4534","IE000M9KFDE8.USD","IE0002270589.USD","SG9999001176.USD","BK4588","SG9999001176.SGD","LU0306806265.USD","PFE","BK4592","BK4007","IE00BBT3K403.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158194244","title":"欧洲委员会批准辉瑞Hympavzi用于治疗伴抑制物的A型或B型血友病成人与青少年","url":"https://stock-news.laohu8.com/highlight/detail?id=1158194244","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158194244?lang=zh_cn&edition=full","pubTime":"2026-05-13 18:46","pubTimestamp":1778669160,"startTime":"0","endTime":"0","summary":"欧洲监管机构已正式批准辉瑞公司的新药Hympavzi，用于治疗伴有抑制物的A型或B型血友病的成年患者及青少年患者。这一批准为面临传统疗法挑战的血友病人群提供了一种新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGXZ57979304.SGD","IE000M9KFDE8.USD","IE00BLSP4239.USD","LU1057294990.SGD","LU0306807586.USD","BK4585","SG9999002224.SGD","LU0234572021.USD","LU1066053197.SGD","LU0306806265.USD","IE00B19Z3581.USD","PFE","LU0321505868.SGD","SG9999003800.SGD","LU0321505439.SGD","LU1023059063.AUD","IE00B3T34201.USD","BK4599","SG9999002232.USD","LU0868494617.USD","BK4534","BK4568","BK4550","LU0122379950.USD","LU1066051498.USD","LU0456855351.SGD","BK4588","LU0058720904.USD","LU1894683348.USD","LU0289739699.SGD","IE00BBT3K403.USD","BK4592","LU0225771236.USD","IE0002270589.USD","SG9999013999.USD","LU1894683264.USD","BK4581","IE00B19Z3B42.SGD","SG9999011175.SGD","SG9999001176.USD","LU0170899867.USD","LU0985481810.HKD","LU0225284248.USD","IE00BLSP4452.SGD","BK4007","BK4533","LU1883839398.USD","SG9999001176.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108516495","title":"辉瑞公司公布三月季度净利润20亿卢比","url":"https://stock-news.laohu8.com/highlight/detail?id=1108516495","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108516495?lang=zh_cn&edition=full","pubTime":"2026-05-12 22:12","pubTimestamp":1778595137,"startTime":"0","endTime":"0","summary":"辉瑞有限公司宣布，将派发每股75卢比的股息。\n公司最新财报显示，在截至三月的季度中，其净利润达到20亿卢比。\n同期，辉瑞来自运营的合并总收入为62.9亿卢比。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225771236.USD","BK4585","LU0234572021.USD","SG9999003800.SGD","SG9999002224.SGD","BK4550","LU0289739699.SGD","BK4534","LU0225284248.USD","LU0170899867.USD","LU0122379950.USD","SG9999001176.SGD","BK4592","PFE","BK4581","SG9999013999.USD","SG9999001176.USD","IE00BLSP4452.SGD","LU0306807586.USD","LU0321505868.SGD","LU1066051498.USD","BK4007","LU1066053197.SGD","SGXZ57979304.SGD","LU1057294990.SGD","LU1883839398.USD","BK4588","SG9999002232.USD","IE00BBT3K403.USD","IE00B3T34201.USD","BK4599","IE0002270589.USD","IE000M9KFDE8.USD","LU1894683348.USD","LU1023059063.AUD","LU1894683264.USD","IE00B19Z3581.USD","LU0058720904.USD","BK4568","LU0306806265.USD","LU0868494617.USD","LU0321505439.SGD","SG9999011175.SGD","LU0456855351.SGD","IE00BLSP4239.USD","IE00B19Z3B42.SGD","LU0985481810.HKD","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157887878","title":"Arvinas与辉瑞携手Rigel Pharmaceuticals，就Veppanu（Vepdegestrant）达成全球独家授权交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1157887878","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157887878?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:01","pubTimestamp":1778583714,"startTime":"0","endTime":"0","summary":"Arvinas Holding Company LLC与辉瑞公司已同Rigel Pharmaceuticals达成一项协议，获得其药物Veppanu（Vepdegestrant）的全球独家权利。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0868494617.USD","SGXZ57979304.SGD","IE00BLSP4452.SGD","BK4534","BK4599","IE00BBT3K403.USD","BK4568","BK4588","SG9999013999.USD","LU0289739699.SGD","LU0985481810.HKD","LU1066051498.USD","LU0122379950.USD","LU0321505868.SGD","LU1066053197.SGD","LU0456855351.SGD","LU0321505439.SGD","SG9999001176.SGD","IE0002270589.USD","LU0306806265.USD","LU0225771236.USD","SG9999002224.SGD","BK4581","LU1894683348.USD","SG9999001176.USD","LU0170899867.USD","BK4592","BK4550","SG9999002232.USD","BK4585","IE00B19Z3581.USD","LU1894683264.USD","BK4533","IE000M9KFDE8.USD","LU0234572021.USD","RIGL","LU1057294990.SGD","LU0306807586.USD","LU1023059063.AUD","ARVN","LU0225284248.USD","LU1883839398.USD","SG9999003800.SGD","PFE","LU0058720904.USD","BK4007","IE00B3T34201.USD","IE00BLSP4239.USD","SG9999011175.SGD","IE00B19Z3B42.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633794147","title":"多家药企高管生变：恒瑞、复星、阿斯利康、辉瑞…","url":"https://stock-news.laohu8.com/highlight/detail?id=2633794147","media":"赛柏蓝","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633794147?lang=zh_cn&edition=full","pubTime":"2026-05-07 19:53","pubTimestamp":1778154780,"startTime":"0","endTime":"0","summary":"01本土制药企业与Biotech迎高管变动恒瑞医药、再鼎医药、百济神州、和铂医药、复星医药映射出了中国创新药发展过程中企业所处的不同阶段。4月16日，恒瑞医药发布公告，正式完成新一届董事会和管理层聘任。复星医药4月2日，复星医药发布首席财务官变更公告，因工作安排调整，陈战宇辞去首席财务官职务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-05-07/doc-inhxatff4708181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00B3T34201.USD","IE00BBT3K403.USD","LU0868494617.USD","LU2236285917.USD","IE000M9KFDE8.USD","ONC","LU1894683264.USD","BK4533","LU2237443465.HKD","LU1829250122.USD","600276","BK4588","LU1066051498.USD","LU2237443622.USD","IE00B19Z3581.USD","LU2462157665.USD","BK4534","LU2417539215.USD","LU0170899867.USD","PFE","LU1066053197.SGD","SG9999001176.USD","LU1883839398.USD","BK4592","LU1057294990.SGD","688235","LU0985481810.HKD","LU2237443978.SGD","BK4599","LU0306807586.USD","LU0306806265.USD","LU2237443382.USD","AZNH","LU0456855351.SGD","LU2237443549.SGD","LU0321505439.SGD","LU1894683348.USD","LU2456880835.USD","LU0234572021.USD","LU0225284248.USD","02196","600196","SG9999003800.SGD","LU0289739699.SGD","LU2237443895.HKD","SG9999002232.USD","SG9999013999.USD","SGXZ57979304.SGD","SG9999001176.SGD","01276","BK4585","IE00B19Z3B42.SGD","IE0002270589.USD","SG9999011175.SGD","LU1023059063.AUD","AZN","LU0321505868.SGD","02142","LU0058720904.USD","LU0225771236.USD","LU0109394709.USD","BK4581","LU0122379950.USD","BK4007","LU0320765992.SGD","SG9999002224.SGD","BK4550","IE00BLSP4452.SGD","LU0889565916.HKD","IE00BLSP4239.USD","06160","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633945459","title":"辉瑞(PFE.US)旧药组合销售增长 Q1营收利润双双超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2633945459","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633945459?lang=zh_cn&edition=full","pubTime":"2026-05-05 21:02","pubTimestamp":1777986138,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，辉瑞公布的第一季度利润超出华尔街预期，主要得益于对过往药物的持续需求。一季度，辉瑞与百时美施贵宝联合销售的血液稀释剂Eliquis的销售额为 21.7 亿美元，同比增长 13%，而此前的估计为 17.6 亿美元。其重磅心脏药物 Vyndamax 第一季度销售额为 16 亿美元，高于此前预估的 16.2 亿美元。最近，辉瑞新冠产品的销售额已从疫情高峰期大幅下滑。辉瑞正致力于精简成本，同时重建产品线以支持未来的增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438218.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0002270589.USD","LU0985481810.HKD","BK4550","BK4568","IE000M9KFDE8.USD","LU0289739699.SGD","LU0321505439.SGD","LU1057294990.SGD","LU0234572021.USD","LU1883839398.USD","IE00B19Z3B42.SGD","IE00BLSP4239.USD","SG9999003800.SGD","SG9999013999.USD","IE00B19Z3581.USD","LU0321505868.SGD","LU0306806265.USD","LU1066051498.USD","BK4533","BK4007","LU0058720904.USD","LU0868494617.USD","BK4592","BK4599","PFE","SGXZ57979304.SGD","SG9999011175.SGD","SG9999001176.SGD","SG9999002224.SGD","IE00BLSP4452.SGD","SG9999002232.USD","LU1894683264.USD","BK4588","LU1066053197.SGD","IE00BBT3K403.USD","IE00B3T34201.USD","BK4585","LU0170899867.USD","BK4534","LU0306807586.USD","LU0225284248.USD","LU0456855351.SGD","LU0122379950.USD","LU0225771236.USD","LU1023059063.AUD","SG9999001176.USD","BK4581","LU1894683348.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633644948","title":"辉瑞(PFE)一季报业绩超预期 全年财务指引维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=2633644948","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633644948?lang=zh_cn&edition=full","pubTime":"2026-05-05 20:25","pubTimestamp":1777983906,"startTime":"0","endTime":"0","summary":"金吾财讯 | 辉瑞 披露 2026 年一季度经营财报，整体盈利与营收均大幅跑赢市场预期。剥离新冠疫苗与新冠口服药相关收入后，辉瑞核心主业经营性营收仍实现 7% 的同比增长，已上市及并购整合产品线内生营收增速更是高达 22%，显示非新冠创新药及并购资产成为增长主力。辉瑞并未调整 2026 年全年业绩预期，维持营收 595 亿 —625 亿美元、调整后每股收益 2.80—3.00 美元的区间，与市场中枢预期基本贴合。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/MjU4MmU0MDcxNDc2ODE0Nzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MjU4MmU0MDcxNDc2ODE0Nzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"20fc0a9e62e1a698162b12bd56d8195a","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300048","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999001176.USD","BK4585","LU0225284248.USD","BK4533","SGXZ57979304.SGD","LU1894683348.USD","SG9999002224.SGD","BK4568","IE00B19Z3B42.SGD","LU1023059063.AUD","IE00B19Z3581.USD","IE000M9KFDE8.USD","LU0306806265.USD","IE00BLSP4452.SGD","LU0306807586.USD","LU0225771236.USD","IE00BBT3K403.USD","IE00BLSP4239.USD","LU1894683264.USD","BK4588","IE0002270589.USD","IE00B3T34201.USD","SG9999013999.USD","BK4581","LU1066053197.SGD","BK4007","SG9999003800.SGD","SG9999001176.SGD","LU1066051498.USD","SG9999002232.USD","LU0321505868.SGD","BK4592","BK4550","LU0170899867.USD","LU0868494617.USD","SG9999011175.SGD","LU1057294990.SGD","LU0234572021.USD","LU0058720904.USD","LU0321505439.SGD","LU0456855351.SGD","LU0985481810.HKD","LU1883839398.USD","LU0289739699.SGD","PFE","BK4534","BK4599","LU0122379950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119333101","title":"辉瑞一季度业绩超预期，重申2026年业绩展望，新产品增长显现","url":"https://stock-news.laohu8.com/highlight/detail?id=1119333101","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119333101?lang=zh_cn&edition=full","pubTime":"2026-05-05 18:53","pubTimestamp":1777978393,"startTime":"0","endTime":"0","summary":"要点辉瑞公布的第一季度盈利和营收均超过预期，并重申了其2026年展望，得益于近期推出及收购的产品实现增长。这家制药巨头正着眼于其管线的长期投资，包括最近以100亿美元收购肥胖症生物科技公司Metsera，以抵消新冠相关产品销售下滑以及老药收入下降的影响。辉瑞今年还专注于若干关键数据发布，包括一款用于肺癌的实验性靶向药物的后期临床试验结果。","market":"us","thumbnail":"https://community-static.tradeup.com/news/cf38973f44e79182ecf2eb704945f794","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/cf38973f44e79182ecf2eb704945f794"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ca0e3dea87604e6a95a3bf5695c5bcab","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194273439","title":"辉瑞重申：第一阶段制造优化项目预计节省约7亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1194273439","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194273439?lang=zh_cn&edition=full","pubTime":"2026-05-05 18:52","pubTimestamp":1777978359,"startTime":"0","endTime":"0","summary":"辉瑞公司维持其成本节约预期，确认通过制造优化计划的第一阶段实施，将继续实现约7亿美元的资金节省。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999002232.USD","LU1066053197.SGD","IE00BLSP4239.USD","LU0289739699.SGD","LU0225771236.USD","BK4581","LU0234572021.USD","LU0058720904.USD","SG9999013999.USD","IE00B19Z3581.USD","BK4534","LU1894683348.USD","IE00BBT3K403.USD","LU0321505439.SGD","LU0321505868.SGD","BK4550","LU0985481810.HKD","LU1066051498.USD","SG9999001176.USD","LU1894683264.USD","LU0868494617.USD","PFE","BK4592","IE00B3T34201.USD","LU0306807586.USD","LU1057294990.SGD","LU0170899867.USD","LU1023059063.AUD","LU0122379950.USD","SG9999001176.SGD","LU0456855351.SGD","IE00BLSP4452.SGD","BK4533","SG9999002224.SGD","BK4007","IE00B19Z3B42.SGD","LU1883839398.USD","BK4568","SG9999011175.SGD","BK4588","LU0225284248.USD","IE0002270589.USD","SGXZ57979304.SGD","SG9999003800.SGD","BK4599","LU0306806265.USD","IE000M9KFDE8.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180071280","title":"辉瑞认为比利时法院关于新冠疫苗合同的裁决对未来每股收益和现金流具有积极影响——预备声明","url":"https://stock-news.laohu8.com/highlight/detail?id=1180071280","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180071280?lang=zh_cn&edition=full","pubTime":"2026-05-05 18:51","pubTimestamp":1777978312,"startTime":"0","endTime":"0","summary":"辉瑞公司表示，比利时法院近期就欧盟成员国Comirnaty疫苗采购合同作出的裁决，将对企业未来每股收益和现金流产生积极推动作用。这一司法裁定为公司的财务前景提供了有力支撑。\n根据预备声明披露，该判决确认了疫苗供应协议的法律效力，有助于稳定辉瑞在欧洲市场的业务预期。公司强调，此项进展将进一步提升其财务稳健性，为股东创造长期价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999001176.SGD","LU0306807586.USD","IE00B19Z3581.USD","IE0002270589.USD","BK4581","LU0225771236.USD","IE00BLSP4239.USD","BK4533","LU0456855351.SGD","IE000M9KFDE8.USD","LU0868494617.USD","BK4007","SG9999002232.USD","BK4588","BK4599","BK4550","SGXZ57979304.SGD","SG9999011175.SGD","LU0058720904.USD","BK4585","PFE","IE00B3T34201.USD","LU0306806265.USD","LU1894683348.USD","IE00BLSP4452.SGD","LU0234572021.USD","LU0225284248.USD","BK4534","BK4568","SG9999003800.SGD","LU0122379950.USD","LU0170899867.USD","IE00B19Z3B42.SGD","LU1057294990.SGD","SG9999013999.USD","LU0985481810.HKD","SG9999002224.SGD","LU0289739699.SGD","LU1066051498.USD","LU1066053197.SGD","LU1894683264.USD","SG9999001176.USD","IE00BBT3K403.USD","LU1883839398.USD","LU1023059063.AUD","BK4592","LU0321505868.SGD","LU0321505439.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137507928","title":"辉瑞完成TCJA汇回税最终支付 4月缴纳约26亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1137507928","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137507928?lang=zh_cn&edition=full","pubTime":"2026-05-05 18:51","pubTimestamp":1777978304,"startTime":"0","endTime":"0","summary":"根据最新披露的声明文件，制药巨头辉瑞公司已于今年4月完成《减税与就业法案》框架下的最后一笔海外利润汇回税缴纳，金额约为26亿美元。这项税务安排标志着该公司对2017年税改法案相关义务的全面履行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306806265.USD","BK4585","LU0868494617.USD","BK4550","LU0985481810.HKD","BK4599","SG9999001176.USD","IE00BLSP4239.USD","LU0321505868.SGD","LU0289739699.SGD","BK4581","LU1057294990.SGD","LU1066053197.SGD","LU1066051498.USD","LU0306807586.USD","IE000M9KFDE8.USD","IE00BBT3K403.USD","BK4534","BK4568","LU1894683348.USD","IE00B3T34201.USD","LU0234572021.USD","BK4592","LU0122379950.USD","LU0225771236.USD","IE00BLSP4452.SGD","LU1883839398.USD","LU1023059063.AUD","SG9999013999.USD","BK4588","SG9999003800.SGD","SG9999002232.USD","PFE","IE00B19Z3B42.SGD","LU0456855351.SGD","SG9999001176.SGD","SG9999011175.SGD","LU1894683264.USD","SGXZ57979304.SGD","LU0225284248.USD","IE0002270589.USD","LU0321505439.SGD","BK4533","LU0058720904.USD","SG9999002224.SGD","IE00B19Z3581.USD","LU0170899867.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174461863","title":"辉瑞：Vyndamax和解协议增强信心，预计2029年起将进入五年高个位数收入复合增长期","url":"https://stock-news.laohu8.com/highlight/detail?id=1174461863","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174461863?lang=zh_cn&edition=full","pubTime":"2026-05-05 18:49","pubTimestamp":1777978183,"startTime":"0","endTime":"0","summary":"辉瑞公司表示，Vyndamax相关和解协议的达成使其更具信心，从2029年开始，公司将迎来为期五年的高个位数收入复合年增长率阶段。这一预期标志着辉瑞在核心产品战略布局上的重要突破，为长期增长路径奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","IE00BBT3K403.USD","BK4592","BK4533","LU0234572021.USD","SG9999011175.SGD","IE00BLSP4239.USD","LU0225284248.USD","BK4550","LU0306807586.USD","LU1894683348.USD","LU0321505868.SGD","LU1894683264.USD","LU0456855351.SGD","LU0985481810.HKD","SG9999001176.USD","BK4007","BK4585","LU1066051498.USD","LU0868494617.USD","SG9999002224.SGD","SG9999001176.SGD","BK4588","LU1023059063.AUD","IE00B19Z3581.USD","IE000M9KFDE8.USD","LU0058720904.USD","LU0122379950.USD","LU0306806265.USD","IE00BLSP4452.SGD","LU0321505439.SGD","LU1066053197.SGD","SG9999013999.USD","BK4568","LU0225771236.USD","LU1883839398.USD","LU1057294990.SGD","LU0289739699.SGD","IE00B3T34201.USD","BK4599","SG9999002232.USD","IE0002270589.USD","LU0170899867.USD","IE00B19Z3B42.SGD","BK4534","SG9999003800.SGD","PFE","SGXZ57979304.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122923228","title":"辉瑞本季度两大法律进展将显著改善2028年后增长前景与现金流预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1122923228","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122923228?lang=zh_cn&edition=full","pubTime":"2026-05-05 18:49","pubTimestamp":1777978159,"startTime":"0","endTime":"0","summary":"辉瑞公司近期宣布，本季度取得两项重大法律进展，这些进展将有效提升公司2028年之后的增长潜力与现金流展望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU0122379950.USD","LU0234572021.USD","LU1883839398.USD","SG9999013999.USD","IE00B19Z3581.USD","BK4585","LU0058720904.USD","IE00B3T34201.USD","LU0868494617.USD","BK4599","LU1066051498.USD","LU0321505868.SGD","PFE","LU0225284248.USD","SG9999002232.USD","BK4550","BK4534","LU0225771236.USD","LU1057294990.SGD","BK4007","SG9999001176.SGD","SG9999001176.USD","BK4588","BK4533","SG9999011175.SGD","SG9999003800.SGD","LU1894683348.USD","LU0456855351.SGD","BK4592","SG9999002224.SGD","LU0170899867.USD","LU0306807586.USD","LU1066053197.SGD","LU0321505439.SGD","IE00BBT3K403.USD","LU1894683264.USD","IE0002270589.USD","IE00BLSP4239.USD","LU0985481810.HKD","IE00B19Z3B42.SGD","LU0306806265.USD","BK4581","IE000M9KFDE8.USD","IE00BLSP4452.SGD","BK4568","SGXZ57979304.SGD","LU1023059063.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141545147","title":"辉瑞2026年首季度斥资25亿美元投入内部研发项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1141545147","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141545147?lang=zh_cn&edition=full","pubTime":"2026-05-05 18:47","pubTimestamp":1777978056,"startTime":"0","endTime":"0","summary":"2026年第一季度，制药巨头辉瑞公司宣布向其内部研发项目投入25亿美元资金。这笔巨额投资将主要用于推进创新药物管线开发，涵盖肿瘤学、疫苗研发及罕见病治疗等前沿领域。公司表示，此举旨在强化其长期科研实力，为未来业绩增长奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0985481810.HKD","IE00BLSP4239.USD","LU1883839398.USD","LU0058720904.USD","BK4534","IE00BBT3K403.USD","LU0170899867.USD","IE000M9KFDE8.USD","LU0234572021.USD","LU1894683348.USD","SG9999013999.USD","SG9999001176.USD","IE00B19Z3581.USD","SG9999001176.SGD","BK4592","SG9999003800.SGD","IE0002270589.USD","LU1023059063.AUD","BK4599","BK4533","BK4581","LU0225284248.USD","BK4007","LU0306806265.USD","IE00B19Z3B42.SGD","LU1066051498.USD","SG9999011175.SGD","SGXZ57979304.SGD","IE00B3T34201.USD","IE00BLSP4452.SGD","LU0122379950.USD","LU1894683264.USD","LU0321505439.SGD","LU0306807586.USD","LU1057294990.SGD","SG9999002232.USD","LU0456855351.SGD","LU1066053197.SGD","BK4588","LU0321505868.SGD","LU0225771236.USD","PFE","SG9999002224.SGD","BK4568","LU0868494617.USD","BK4550","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183147930","title":"辉瑞启动全球生物制药业务商业组织架构调整 首季起实施","url":"https://stock-news.laohu8.com/highlight/detail?id=1183147930","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183147930?lang=zh_cn&edition=full","pubTime":"2026-05-05 18:46","pubTimestamp":1777978005,"startTime":"0","endTime":"0","summary":"全球制药巨头辉瑞公司宣布，自今年第一季度起，其全球生物制药业务板块的商业组织架构已启动战略性调整。此次重组涉及商业运营体系的优化与革新，旨在提升组织效能与市场响应速度。\n作为跨国药企的领军者，辉瑞此次架构调整聚焦于全球生物制药商业团队的重组，通过整合资源、优化流程强化企业在全球医药市场的竞争力。该举措预计将进一步提升运营效率，为未来业务增长注入新动能。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999001176.SGD","LU0306807586.USD","IE00B19Z3581.USD","IE0002270589.USD","BK4581","LU0225771236.USD","IE00BLSP4239.USD","BK4533","LU0456855351.SGD","IE000M9KFDE8.USD","LU0868494617.USD","BK4007","SG9999002232.USD","BK4588","BK4599","BK4550","SGXZ57979304.SGD","SG9999011175.SGD","LU0058720904.USD","BK4585","PFE","IE00B3T34201.USD","LU0306806265.USD","LU1894683348.USD","IE00BLSP4452.SGD","LU0234572021.USD","LU0225284248.USD","BK4534","BK4568","SG9999003800.SGD","LU0122379950.USD","LU0170899867.USD","IE00B19Z3B42.SGD","LU1057294990.SGD","SG9999013999.USD","LU0985481810.HKD","SG9999002224.SGD","LU0289739699.SGD","LU1066051498.USD","LU1066053197.SGD","LU1894683264.USD","SG9999001176.USD","IE00BBT3K403.USD","LU1883839398.USD","LU1023059063.AUD","BK4592","LU0321505868.SGD","LU0321505439.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178819416","title":"BioNTech宣布2026年新冠疫苗生产将全面移交辉瑞 德国本土不再设生产线","url":"https://stock-news.laohu8.com/highlight/detail?id=1178819416","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178819416?lang=zh_cn&edition=full","pubTime":"2026-05-05 18:45","pubTimestamp":1777977948,"startTime":"0","endTime":"0","summary":"BioNTech SE近日披露重大生产调整方案，计划于2026年内将新冠疫苗的完整生产流程转移至合作伙伴辉瑞旗下生产基地。这意味着该疫苗在德国境内的生产线将全面停止运作。\n此次战略调整标志着两家企业在疫情后期对疫苗生产布局的重新规划。作为曾经主导欧洲疫苗供应的德国生物技术公司，BioNTech将把生产重心完全转向技术研发与创新平台建设，而辉瑞将承担后续所有生产环节的全球供应链管理。\n业内观察人士指出，这一转变既反映了新冠疫苗需求常态化的市场现实，也体现出生物医药行业全球分工的深化趋势。两家企业未来将继续保持研发端的紧密合作，但生产职能的集中化将有助于优化成本结构并提升运营效率。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023059063.AUD","SG9999002224.SGD","SG9999001176.USD","BK4585","BK4533","LU0321505868.SGD","IE00B19Z3B42.SGD","LU0456855351.SGD","BK4139","LU0225771236.USD","SG9999013999.USD","LU1894683348.USD","IE0002270589.USD","LU1066051498.USD","IE00B19Z3581.USD","LU1883839398.USD","LU0868494617.USD","BK4548","LU0306807586.USD","SG9999002232.USD","SG9999011175.SGD","BNTX","IE00BLSP4452.SGD","SG9999001176.SGD","BK4535","SG9999003800.SGD","LU1894683264.USD","BK4534","BK4581","LU0985481810.HKD","BK4599","LU0289739699.SGD","LU0306806265.USD","LU1057294990.SGD","BK4568","LU0058720904.USD","BK4592","BK4007","IE00B3T34201.USD","LU0225284248.USD","LU0321505439.SGD","SGXZ57979304.SGD","IE00BLSP4239.USD","LU0170899867.USD","BK4588","LU0234572021.USD","BK4550","LU1066053197.SGD","PFE","IE00BBT3K403.USD","LU0122379950.USD","IE000M9KFDE8.USD","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109723577","title":"辉瑞Elrexfio显著改善双重疗法暴露的复发或难治性多发性骨髓瘤患者的无进展生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=1109723577","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109723577?lang=zh_cn&edition=full","pubTime":"2026-04-29 18:47","pubTimestamp":1777459620,"startTime":"0","endTime":"0","summary":"辉瑞公司旗下药物Elrexfio在针对复发或难治性多发性骨髓瘤患者的临床研究中取得突破性进展。该研究聚焦于已对两种主要治疗类别产生耐药性的患者群体，结果显示Elrexfio疗法能显著延长患者的无进展生存期。\n这一发现为临床治疗提供了新的方向，尤其对现有疗法反应不佳的患者具有重要意义。无进展生存期是衡量肿瘤药物疗效的关键指标，其显著改善预示着该药物可能改变现有治疗格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306806265.USD","BK4585","LU0868494617.USD","BK4550","LU0985481810.HKD","BK4599","SG9999001176.USD","IE00BLSP4239.USD","LU0321505868.SGD","LU0289739699.SGD","BK4581","LU1057294990.SGD","LU1066053197.SGD","LU1066051498.USD","LU0306807586.USD","IE000M9KFDE8.USD","IE00BBT3K403.USD","BK4534","BK4568","LU1894683348.USD","LU0234572021.USD","LU0122379950.USD","BK4592","LU0225771236.USD","IE00BLSP4452.SGD","LU1883839398.USD","LU1023059063.AUD","SG9999013999.USD","BK4588","SG9999003800.SGD","SG9999002232.USD","PFE","IE00B19Z3B42.SGD","LU0456855351.SGD","SG9999001176.SGD","SG9999011175.SGD","LU1894683264.USD","SGXZ57979304.SGD","LU0225284248.USD","IE0002270589.USD","LU0321505439.SGD","BK4533","LU0058720904.USD","SG9999002224.SGD","IE00B19Z3581.USD","LU0170899867.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130123372","title":"和解协议助力 辉瑞预期2028年至2031年中营收将保持相对稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1130123372","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130123372?lang=zh_cn&edition=full","pubTime":"2026-04-28 22:18","pubTimestamp":1777385934,"startTime":"0","endTime":"0","summary":"得益于近期达成的和解协议，辉瑞公司预计其营业收入将从2028年起至2031年中期保持相对平稳态势。这一重大调整标志着公司对未来四年财务表现的前瞻性规划，反映出战略布局对营收韧性的积极影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999011175.SGD","BK5011","SG9999002232.USD","LU0868494617.USD","BK4592","IE00B19Z3B42.SGD","SG9999003800.SGD","IE0002270589.USD","BK4588","LU1023059063.AUD","PFE","LU0122379950.USD","IE00BLSP4239.USD","BK4599","LU0289739699.SGD","BK4007","LU0225284248.USD","LU0456855351.SGD","BK4550","LU0234572021.USD","SG9999002224.SGD","LU1057294990.SGD","LU1066051498.USD","LU1894683264.USD","LU1894683348.USD","LU0225771236.USD","BK4585","BK4568","LU0058720904.USD","LU0306807586.USD","LU0321505439.SGD","LU0321505868.SGD","SG9999001176.USD","IE00B19Z3581.USD","BK4533","IE00BLSP4452.SGD","LU0306806265.USD","IE00BBT3K403.USD","SGXZ57979304.SGD","SG9999013999.USD","LU0170899867.USD","LU1883839398.USD","LU0985481810.HKD","BK4534","LU1066053197.SGD","BK4581","IE00B0JY6N72.USD","SG9999001176.SGD","IE000M9KFDE8.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153184090","title":"财报前瞻｜辉瑞本季度营收预计小幅下滑，机构观点看多","url":"https://stock-news.laohu8.com/highlight/detail?id=1153184090","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153184090?lang=zh_cn&edition=full","pubTime":"2026-04-28 08:20","pubTimestamp":1777335636,"startTime":"0","endTime":"0","summary":"辉瑞将于2026年05月05日美股盘前发布最新季度财报，市场聚焦盈利修复与管线催化的实际兑现。一致预期显示，辉瑞本季度营收预计为137.89亿美元，同比下降0.85%；调整后每股收益预计为0.72美元，同比增长8.45%；息税前利润预计为54.68亿美元，同比增长14.26%，上季度财报未披露针对本季度的毛利率与净利润定量指引，相关预测数据暂不可得。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜辉瑞本季度营收预计小幅下滑，机构观点看多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pfizer.com","stockEarnings":[{"period":"1week","weight":-0.0215},{"period":"1month","weight":-0.0505},{"period":"3month","weight":-0.055},{"period":"6month","weight":0.0359},{"period":"1year","weight":0.1351},{"period":"ytd","weight":0.0426}],"compareEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":0.0819},{"period":"3month","weight":0.0896},{"period":"6month","weight":0.1047},{"period":"1year","weight":0.2649},{"period":"ytd","weight":0.0886}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"辉瑞公司于1942年6月2日根据特拉华州法律成立。公司是一家以研究为基础的全球性生物制药公司。公司运用科学和全球资源，通过发现、开发、制造和分销保健产品（包括创新药物和疫苗），为人们带来延长和显著改善其生活的疗法。公司在发达国家和新兴市场开展工作，致力于促进健康、预防、治疗和治愈这个时代最令人恐惧的疾病。公司与医疗保健提供商、政府和当地社区合作，支持并扩大在全球范围内获得可靠、负担得起的医疗保健服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.456522,"avgChangeRate":0.002542},{"month":2,"riseRate":0.456522,"avgChangeRate":-0.005934},{"month":3,"riseRate":0.608696,"avgChangeRate":0.014732},{"month":4,"riseRate":0.574468,"avgChangeRate":0.016819},{"month":5,"riseRate":0.489362,"avgChangeRate":0.006993},{"month":6,"riseRate":0.5,"avgChangeRate":0.002798},{"month":7,"riseRate":0.478261,"avgChangeRate":0.011357},{"month":8,"riseRate":0.456522,"avgChangeRate":0.0002},{"month":9,"riseRate":0.456522,"avgChangeRate":0.004432},{"month":10,"riseRate":0.630435,"avgChangeRate":0.013042},{"month":11,"riseRate":0.695652,"avgChangeRate":0.028255},{"month":12,"riseRate":0.5,"avgChangeRate":0.008452}],"exchange":"NYSE","name":"辉瑞","nameEN":"Pfizer"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供辉瑞(PFE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"辉瑞,PFE,辉瑞股票,辉瑞股票老虎,辉瑞股票老虎国际,辉瑞行情,辉瑞股票行情,辉瑞股价,辉瑞股市,辉瑞股票价格,辉瑞股票交易,辉瑞股票购买,辉瑞股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供辉瑞(PFE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}